High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$36.3M
$36,310,124
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 Sell
|
2026-03-31 | $108,879 | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
Other
|
2026-03-31 | $715,200 | M | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
Other
|
2026-03-31 | $627,657 | M | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Soteropoulos Paula
• Director
10b5-1 Sell
2026-03-31
$47,986
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Director
10b5-1 Sell
|
2026-03-31 | $47,986 | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 Sell
|
2026-03-31 | $618,625 | S | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Savitz Ryan
• CFO
10b5-1 SellΔOwn -72.9%
2026-03-31
$1,646,493Large
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 SellΔOwn -72.9%
|
2026-03-31 | $1,646,493Large | S | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Savitz Ryan
• CFO
10b5-1 SellΔOwn -69.1%
2026-03-31
$5,017,220Whale
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 SellΔOwn -69.1%
|
2026-03-31 | $5,017,220Whale | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 Sell
|
2026-03-31 | $195,999 | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 Sell
|
2026-03-31 | $65,088 | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Director
Other
|
2026-03-31 | $5,056 | M | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 Sell
|
2026-03-31 | $119,171 | S | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Savitz Ryan
• CFO
10b5-1 SellΔOwn -19.3%
2026-03-31
$1,721,120Large
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 SellΔOwn -19.3%
|
2026-03-31 | $1,721,120Large | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Director
Other
|
2026-03-24 | $232,893 | M | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Soteropoulos Paula
• Director
10b5-1 Sell
2026-03-24
$2,153,712Large
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Director
10b5-1 Sell
|
2026-03-24 | $2,153,712Large | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CEO
Other
|
2026-03-16 | $399,990 | M | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CEO
Other
|
2026-03-16 | $99,985 | M | Form 4 |
|
DNTH
M
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
Other
2026-03-12
$89,400
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
Other
|
2026-03-12 | $89,400 | M | Form 4 |
|
DNTH
M
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
Other
2026-03-12
$275,875
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
Other
|
2026-03-12 | $275,875 | M | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
10b5-1 Sell
2026-03-12
$2,756,468Large
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
10b5-1 Sell
|
2026-03-12 | $2,756,468Large | S | Form 4 |
|
DNTH
M
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
Other
2026-03-12
$181,388
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
Other
|
2026-03-12 | $181,388 | M | Form 4 |
|
DNTH
M
Dianthus Therapeutics, Inc. /DE/
CARR EDWARD
• Officer • CHIEF ACCOUNTING OFFICER
Other
2026-03-12
$289,334
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • CHIEF ACCOUNTING OFFICER
Other
|
2026-03-12 | $289,334 | M | Form 4 |
|
DNTH
M
Dianthus Therapeutics, Inc. /DE/
CARR EDWARD
• Officer • CHIEF ACCOUNTING OFFICER
Other
2026-03-12
$386,225
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • CHIEF ACCOUNTING OFFICER
Other
|
2026-03-12 | $386,225 | M | Form 4 |
|
DNTH
M
Dianthus Therapeutics, Inc. /DE/
CARR EDWARD
• Officer • CHIEF ACCOUNTING OFFICER
Other
2026-03-12
$217,700
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • CHIEF ACCOUNTING OFFICER
Other
|
2026-03-12 | $217,700 | M | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
CARR EDWARD
• Officer • CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -36.3%
2026-03-12
$1,279,415Large
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -36.3%
|
2026-03-12 | $1,279,415Large | S | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
CARR EDWARD
• Officer • CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -84.3%
2026-03-12
$1,918,264Large
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -84.3%
|
2026-03-12 | $1,918,264Large | S | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
CARR EDWARD
• Officer • CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -88.5%
2026-03-12
$319,481
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -88.5%
|
2026-03-12 | $319,481 | S | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
CARR EDWARD
• Officer • CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -40.0%
2026-03-12
$16,676
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -40.0%
|
2026-03-12 | $16,676 | S | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
CARR EDWARD
• Officer • CHIEF ACCOUNTING OFFICER
10b5-1 Sell
2026-03-12
$25,659
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • CHIEF ACCOUNTING OFFICER
10b5-1 Sell
|
2026-03-12 | $25,659 | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CEO
Other
|
2026-03-12 | $823,551 | M | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Garcia Marino
• CEO
10b5-1 SellΔOwn -35.4%
2026-03-12
$3,510,418Large
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CEO
10b5-1 SellΔOwn -35.4%
|
2026-03-12 | $3,510,418Large | S | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Garcia Marino
• CEO
10b5-1 SellΔOwn -82.5%
2026-03-12
$5,355,360Whale
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CEO
10b5-1 SellΔOwn -82.5%
|
2026-03-12 | $5,355,360Whale | S | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Garcia Marino
• CEO
10b5-1 SellΔOwn -92.1%
2026-03-12
$1,056,950Large
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CEO
10b5-1 SellΔOwn -92.1%
|
2026-03-12 | $1,056,950Large | S | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Garcia Marino
• CEO
10b5-1 SellΔOwn -18.2%
2026-03-12
$16,676
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CEO
10b5-1 SellΔOwn -18.2%
|
2026-03-12 | $16,676 | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CEO
10b5-1 Sell
|
2026-03-12 | $76,977 | S | Form 4 |
|
DNTH
M
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
Other
2026-03-12
$67,503
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
Other
|
2026-03-12 | $67,503 | M | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
Other
|
2025-12-04 | $168,800 | M | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
Equity Compensation
|
2025-12-04 | $0 | M | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 Sell
|
2025-12-04 | $903,600 | S | Form 4 |
|
DNTH
M
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
Other
2025-11-14
$816,244
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
Other
|
2025-11-14 | $816,244 | M | Form 4 |
|
DNTH
M
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
Other
2025-11-14
$720,332
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
Other
|
2025-11-14 | $720,332 | M | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
10b5-1 SellΔOwn -96.5%
2025-11-14
$4,158,442Large
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
10b5-1 SellΔOwn -96.5%
|
2025-11-14 | $4,158,442Large | S | Form 4 |
|
DNTH
M
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
Other
2025-11-14
$689,688
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
Other
|
2025-11-14 | $689,688 | M | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
10b5-1 SellΔOwn -28.6%
2025-11-13
$936,743
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
10b5-1 SellΔOwn -28.6%
|
2025-11-13 | $936,743 | S | Form 4 |
|
DNTH
M
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
Other
2025-11-13
$63,099
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
Other
|
2025-11-13 | $63,099 | M | Form 4 |
|
DNTH
M
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
Other
2025-11-13
$708,774
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
Other
|
2025-11-13 | $708,774 | M | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
10b5-1 SellΔOwn -82.3%
2025-11-13
$700,687
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
10b5-1 SellΔOwn -82.3%
|
2025-11-13 | $700,687 | S | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
10b5-1 SellΔOwn -65.5%
2025-11-13
$1,584,016Large
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
10b5-1 SellΔOwn -65.5%
|
2025-11-13 | $1,584,016Large | S | Form 4 |